AZ and Theragnostics in collaboration

Theragnostics and AstraZeneca have agreed terms for a license agreement for intellectual property facilitating Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled Poly (ADP-Ribose) Polymerase inhibitors with an option to an exclusive license for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi.
Theragnostics CEO, Greg Mullen, said: “Theragnostics’ strategy is to develop novel diagnostic imaging agents and targeted radionuclide therapies to improve treatment of a range of cancers. This agreement with AstraZeneca strengthens our IP estate and enables us to accelerate the development of our PARPi therapy and diagnostic portfolio which has the potential to offer new and expanded treatment options to patients in a number of cancers.”
Theragnostics COO, Gareth Smith, said: “We believe that a radionuclide PARPi therapy will work independently of DNA mutations associated with heightened PARPi activity, such as BRCA1/BRCA2 and will avoid development of treatment resistance. Therefore, the number of patients benefiting from PARPi therapy could significantly expand.”